SET and colorectal carcinoma: Moreover, the prevalence of SET overexpression in the subgroup of patients with methacronous metastases was 16.1%, which is markedly lower than the prevalence of 28.1% previously reported in CRC patients with synchronous metastases at diagnosis [12].